The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R03 | Drugs for obstructive airway diseases | |
| 3 | R03D | Other systemic drugs for obstructive airway diseases | |
| 4 | R03DC | Leukotriene receptor antagonists |
| Code | Title | |
|---|---|---|
| R03DC01 | Zafirlukast | |
| R03DC02 | Pranlukast | |
| R03DC03 | Montelukast | |
| R03DC04 | Ibudilast | |
| R03DC53 |
| Active Ingredient | Description | |
|---|---|---|
| Ibudilast |
|
|
| Montelukast |
Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. ฮคhe CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. |
|
| Pranlukast |
|
|
| Zafirlukast |
Zafirlukast is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD4 and LTE4), components of slowreacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ACCOLATE Coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
| MONKASTA Film-coated tablet | Medicines Authority (MT) | MPI, EU: SmPC | |
| SINGULAIR Tablet / Chewable Tablet / Granule | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
